Daewoong Pharmaceutical has expanded NABOTA exports to seven Middle Eastern countries, completing a comprehensive sweep of Gulf Cooperation Council (GCC) markets. The move marks a new record for Korean botulinum toxin exports and reflects intensifying competition for market share outside the U.S. and Europe.
NABOTA's international push—backed by aggressive pricing and distribution partnerships—directly challenges AbbVie's BOTOX and Galderma's Dysport in regions where brand loyalty is less entrenched and price sensitivity is higher. The GCC markets, driven by high per-capita aesthetic spending and growing medical-tourism flows, represent a strategic beachhead for non-Western toxin manufacturers.